Lucid Diagnostics shareholders approve increase in authorized common shares from 300M to 400M

Lucid Diagnostics Inc.

Amendment approved: 152,941,468 for, 12,113,250 against, 382,419 abstain; effective June 24, 2026.
All three Class B director nominees re-elected: James L. Cox, John R. Palumbo, Ronald M. Sparks.
Ratification of CBIZ CPAs P.C. as independent auditor for FY 2025 approved (161.8M votes for).
Approximately 84.7% of outstanding shares represented at the annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.